The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
Mayo Clinic
Hoffmann-La Roche
Tizona Therapeutics, Inc
UNC Lineberger Comprehensive Cancer Center
Novartis
Inhibrx Biosciences, Inc
VM Oncology, LLC
Roswell Park Cancer Institute
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Compugen Ltd
Thomas Jefferson University
Intensity Therapeutics, Inc.
NextCure, Inc.
Inhibrx Biosciences, Inc
iTeos Therapeutics
Rutgers, The State University of New Jersey
Celldex Therapeutics
University of California, San Francisco
R-Pharm
Corvus Pharmaceuticals, Inc.
Cantargia AB
Kineta Inc.
Incyte Corporation
Incyte Corporation